Foslevodopa/Foscarbidopa Improves Pain in People With Advanced Parkinson’s Disease Who Have Uncontrolled Motor Fluctuations: Interim Results From the Real-World ROSSINI Study (P3-17.006)

Key Points

• The central aim is to assess changes in Parkinson’s disease-related pain following continuous subcutaneous infusion of foslevodopa/foscarbidopa.
• Intervention involved 24-hour/day continuous subcutaneous infusion of foslevodopa/foscarbidopa.
• Population consists of individuals with advanced Parkinson’s disease and uncontrolled motor fluctuations.
• Interim results evaluated the effectiveness of the treatment.
• Pain levels significantly decreased after the initiation of treatment, indicating effective pain management.
• Specific numerical results are not detailed in the abstract.